Cargando…

PARP inhibition and immunotherapy: a promising duo in fighting cancer

Detalles Bibliográficos
Autores principales:	Phillipps, Jordan, Zhou, Alice Y., Butt, Omar H., Ansstas, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583004/ https://www.ncbi.nlm.nih.gov/pubmed/37859734 http://dx.doi.org/10.21037/tcr-23-726

Ejemplares similares

Homologous Recombination Deficiency (HRD) in Cutaneous Oncology
por: Akinjiyan, Favour A., et al.
Publicado: (2023)

Case Report: Stereotactic body radiation treatment for immunotherapy escaped oligometastatic progression in cutaneous melanoma and merkel cell carcinoma
por: Khaddour, Karam, et al.
Publicado: (2023)

Nanogenomics and Artificial Intelligence: A Dynamic Duo for the Fight Against Breast Cancer
por: Al-Sowayan, Batla S., et al.
Publicado: (2021)

Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Tarlatamab: the promising immunotherapy on its way from the lab to the clinic
por: Tang, Daolin, et al.
Publicado: (2023)

Taking it up a notch: a promising immunotherapy against small cell lung cancer
por: Apaydin, Alanisse A., et al.
Publicado: (2023)

PARP inhibitors as a radiosensitizer: a future promising approach in prostate cancer?
por: Angel, Martin, et al.
Publicado: (2021)

Graphene supremacy: the duo duo
por: Zhang, Fan, et al.
Publicado: (2022)

Platelets—Disarmed guardians in the fight against the plague
por: Assinger, Alice
Publicado: (2020)

Polyploidy in Lung Regeneration: Double Trouble or Dynamic Duo?
por: Zemans, Rachel L.
Publicado: (2022)

Dúo /
por: Rivas, Humberto
Publicado: (1978)

Dúo
por: Colette, 1873-1954

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios
por: Khaddour, Karam, et al.
Publicado: (2022)

Exosomes: Biological Carriers and Promising Tools for Cancer Immunotherapy
por: Saleh, Reem, et al.
Publicado: (2020)

Bacterial therapy: a promising strategy for cancer immunotherapy
por: Wang, Yinsong
Publicado: (2023)

A promising technique to improve and expand the practice of colposcopy to help the global fight against cervical cancer
por: Teixeira, Julio Cesar, et al.
Publicado: (2022)

Antibiotics and Missed Etiological Diagnosis of Infective Endocarditis: A Dangerous Duo
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2022)

Capitalizing on ATRX loss in glioma via PARP inhibition: Comment on “Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity” by Garbarino et al.
por: Zalenski, Abigail A, et al.
Publicado: (2021)

PARP inhibitors, use early in the first-line maintenance therapy setting but with caution
por: Giudice, Elena, et al.
Publicado: (2023)

The Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

PARP inhibitors are not all equal
por: Dent, Paul
Publicado: (2013)

Duos & transcriptions
por: Schubert, Franz, 1797-1828
Publicado: (1995)

Duos & cantates
por: Carissimi, Giacomo, 1605-1674
Publicado: (1987)

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer
por: Veneziani, Ana C., et al.
Publicado: (2023)

Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunotherapy relapsed melanoma with detected homologous recombination deficiency
por: Khaddour, Karam, et al.
Publicado: (2021)

CAR-macrophage: An extensive immune enhancer to fight cancer
por: Wang, Shuhang, et al.
Publicado: (2022)

Understanding HAIs: Ally proteins in the fight against cancer
por: Nonboe, Annika W., et al.
Publicado: (2022)

Lung cancer in India: Current status and promising strategies
por: Parikh, P. M., et al.
Publicado: (2016)

How SOLID is the immune system’s response to the deadly duo of lung cancer and SARS-CoV-2?
por: Narvel, Hiba, et al.
Publicado: (2022)

A mighty (ochondrial) fight?
por: Piomelli, Daniele
Publicado: (2014)

Food Fights and Femur Wars
Publicado: (2001)

Fighting pandemics with digital epidemiology
por: Tarkoma, Sasu, et al.
Publicado: (2020)

Radiation and immunotherapy: united as one in the fight against cancer
por: Amini, Arya, et al.
Publicado: (2021)

PARP6 inhibition as a strategy to exploit centrosome clustering in cancer cells?
por: Wang, Zebin, et al.
Publicado: (2019)

If the treatment works, do we need to know why?: the promise of immunotherapy for experimental medicine
por: Ehrenstein, Michael R., et al.
Publicado: (2007)

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
por: Ray-Coquard, Isabelle, et al.
Publicado: (2020)

Safri Duo : the remix edition
Publicado: (2002)

Chemotherapy tips the scale in favour of cancer‐fighting B cells
por: Rui, Ke, et al.
Publicado: (2023)

Immunotherapy in cervical cancer: the advent of precision medicine
por: De Felice, Francesca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vbnrd3nl41o7louk77po2fvo44